Inspired by BMD with in-frame mutant DMD, recent studies have demonstrated that CRISPR/Cas9- or Cas12a-mediated removal of one or more exons to reframe mutant DMD restores dystrophin expression in cultured cells from DMD patients and in animal models of the disease [20–27]. This evidence concerns the gene DMD and Becker muscular dystrophy.